PHIO (STOCKS)
Phio Pharmaceuticals Corp. Common Stock
$1.090000
+0.010000 (+0.93%)
Prev close: $1.080000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert J. Bitterman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $13.40M
- Employees
- 5
- P/E (TTM)
- -0.81
- P/B (TTM)
- 1.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.36 | $-0.37 | +0.0072 | +1.96% |
|
Mar 2026 (Q1)
|
$-0.34 | $-0.24 | -0.1003 | -41.84% |
|
Dec 2025 (Q4)
|
$-0.25 | $-0.35 | +0.0938 | +27.05% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.46 | +0.0190 | +4.14% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $13.47M |
| Research and Development | $8.53M |
| Other Operating Expenses | $4.94M |
| Operating Income/Loss | -$13.47M |
| Income/Loss From Continuing Operations After Tax | -$12.90M |
| Income/Loss From Continuing Operations Before Tax | -$12.90M |
| Net Income/Loss | -$12.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$12.90M |
| Net Income/Loss Available To Common Stockholders, Basic | -$12.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.29 |
| Basic Average Shares | 29,827,967 |
| Assets | $14.31M |
| Current Assets | $14.30M |
| Noncurrent Assets | $9.00K |
| Fixed Assets | $9.00K |
| Liabilities | $1.71M |
| Current Liabilities | $1.71M |
| Accounts Payable | $901.00K |
| Other Current Liabilities | $804.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $12.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $12.60M |
| Liabilities And Equity | $14.31M |
| Net Cash Flow From Operating Activities | -$12.20M |
| Net Cash Flow From Operating Activities, Continuing | -$12.20M |
| Net Cash Flow From Investing Activities | -$4.00K |
| Net Cash Flow From Investing Activities, Continuing | -$4.00K |
| Net Cash Flow From Financing Activities | $22.46M |
| Net Cash Flow From Financing Activities, Continuing | $22.46M |
| Net Cash Flow | $10.26M |
| Net Cash Flow, Continuing | $10.26M |
| Comprehensive Income/Loss | -$12.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$12.90M |
| Other Comprehensive Income/Loss | $0.00 |